The overall prognosis of Henoch-Schoenlein purpura (HSP) is favorable, but severe nephritis has a high risk of progression to end stage renal failure. Recent studies emphasize the importance of early treatment in children with severe HSP nephritis, but the treatment of severe HSP nephritis still remains controversial due to the rarity of randomized controlled studies in this field. Nevertheless, several intensive therapies, such as intravenous highdose methylprednisolone pulse, immunosuppressive/cytotoxic drugs, fibrinolytic therapy, anticoagulants, antiplatelet agent and plasma exchange, have been used in children with severe HSP nephritis. In this review, we focus on the treatment of severe HSP nephritis in children. (J Korean Soc Pediatr Nephrol 2010;14:10-21) 
Introduction
Henoch-Schoenlein purpura (HSP) is the most common form of immune-mediated systemic vasculitis in children, which mainly affects the skin, joints, gastrointestinal tract and kidney [1] . The overall prognosis of HSP is favorable, but the long-term outcome is dependent on the degree of renal involvement [2] [3] [4] [5] . The incidence of renal involvement varies from 20 to 100% [6] [7] [8] [9] . Overall, an estimated 2% of children with HSP progress to centers require hemodialysis [6] . Mild HSPN generally does not require aggressive treatment due to a favorable course of the disease [5, 10] . However, long-term studies have shown that even mild renal symptoms at the onset of HSP could lead to an unfavorable prognosis after decades [3, 4] . Therefore, the patients with severe HSPN may require more aggressive therapies. Some authors suggested that treatment should be started early in the course of HSPN before glomerular crescents become fibrous [11] .
Although evidence-based assessment of treatment options for children with IgA nephropathy has been studied [12, 13] , there has been only one randomized controlled study in Treatment of Severe Henoch-Schoenlein Purpura Nephritis in Children severe HSPN [14] , and the treatment of severe HSPN still remains controversial.
In this review, we summarize the previous studies on the treatment of severe HSPN, although the efficacy of several drugs has mostly been shown in case series, and suggest a clinical approach to patients with severe HSPN. Clinical improvement, such as reduction of proteinuria, has been a main therapeutic aim of many renal diseases [18] . In HSPN, however, some long-term studies have shown that clinical recovery does not inevitably mean favorable long-term outcome [3, 4] . Therefore, we performed a study to elucidate the differences between clinical improvement and histological regression [19] . In this study, nineteen of the 20 patients with crescentic HSPN had a favor- [19] . These results suggest that more strict determination of favorable prognosis would be imperative.
What is intensive therapy and when should we start intensive therapy?
Intensive therapy includes intravenous highdose methylprednisolone pulse, immunosuppressive drugs (e.g. cyclophosphamide, azathioprine, cyclosporin), fibrinolytic therapy (e.g. ISKDC grade at the second biopsy [36] . However, these two studies could not prove the disadvantage of delayed treatment due to small case series without controls [25, 36] . Therefore, we performed another study [19] and showed that early treatment with immunosuppressants was an important factor to achieve histological regression by decreasing chronic renal injury. In this study, the chronicity index at the second biopsy correlated positively with the time immunosuppressive therapy was started. Ronkainen et al. also demonstrated that the only difference between four patients who achieved a stable remission after cyclosporin therapy and three patients who became cyclosporin dependent was that cyclosporin had been started significantly earlier in the former group than in the latter [34] . Therefore, early immunosuppressive therapy should be considered in children with severe HSPN.
The application of intensive therapy 1) Methylprednisolone pulse therapy (MPT)
MPT has been used as a sole agent [11] protein excretion, and chronic renal injury [11, 19] .
2) Cyclophosphamide
Cyclophosphamide has also been used in combinations with prednisone or other regi- [28, 29] . They applied urokinase to these patients since glomerular fibrinogen deposits are frequently present in crescentic HSPN [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . We found that the decrease of fibrinogen deposition was associated with histological regression of crescentic HSPN and the age at the onset of HSPN was correlated positively with the fibrinogen deposition at the second biopsy [19] . In this study, however, we could not show the exact role of fibrinogen deposition in the pathogenesis of crescentic HSPN. To elucidate this, we postulated that there would be some differences in crescent formation and glomerular fibrinogen deposition among HSPN patients, and fibrinolytic therapy should be done according to the characteristics of an individual patient since HSPN is a heterogenous disease with many histopathological presentations and crescents associated with HSPN are not always fibrinogen-dependent [40] . Therefore, we reclassified the patients with crescentic HSPN into two groups according to the subsequent course of fibrinogen deposits: group I (N=9) with no or decreased deposition and group II (N=12) with persistent or increased deposition [40] . Although other authors had treated the patients according to the fibrinogen deposits at the first biopsy, our results demonstrated the heterogenous serial changes of fibrinogen deposition between the first and second biopsy: 2 patients had no fibrinogen deposits throughout the course of the disease and 7 showed diminution or disappearance of crescents and fibrinogen deposits with only immunosuppressants in group I, whereas 3 patients who had shown no fibrinogen deposits at the first biopsy developed new fibrinogen deposits at the second biopsy, and 9 had persistent or increased fibrinogen deposits in spite of immunosuppressants in group II [40] .
Therefore, we were interested in discriminating these two groups, and we found that an age more than 9 years was the only factor statistically significant related to the persistent or increased fibrinogen deposition. This study also demonstrated that changes in the percentage of crescents correlated positively with the intensity of fibrinogen deposits at the second biopsy [40] . In this point, fibrinolytic therapy reported that ACE inhibitors could be an effective alternative for reducing proteinuria in 9 children with prolonged nephropathy, including HSPN [50] . In this study, proteinuria was initially in the nephrotic range, but fell significantly after 6 months and at the end of the treatment without the decrease in glomerular filtration rate and adverse reactions in all patients. ACE inhibitors has also been used with other immunosuppressants safely [34, 35, 51] in children with severe HSPN. Therefore, ACE inhibitors could be used for renal protection in HSPN patients with severe proteinuria, because nephrotic syndrome at onset or increasing proteinuria during follow-up was associated with renal progression in HSPN [14, 21, 48] .
7. Persistent proteinuria after initial intensive therapy: observation or further immunosuppression?
In addition to Coppo et al. s study [48] , Tar 
Conclusions
Severe HSPN has a high risk of progression to end stage renal failure and recent studies emphasize the importance of early treatment in children with severe HSPN [11, 17, 19] .
Considering the unfavorable long-term outcome even in HSPN patients with mild renal symptoms at onset [3, 4] , the treatment of severe HSPN should be started early during the course of HSPN before the crescents become fibrous, as suggested by Niaudet et al. [11] . However, due to the rarity of randomized 
